share_log

Cosmos Health Enters Into A Material Definitive Agreement With Cana Laboratories Pursuant To The Binding Letter Of Intent; The Next Phase Is The Execution Of A Stock Purchase Agreement To Be Concluded No Later Than March 31, 2023

Cosmos Health Enters Into A Material Definitive Agreement With Cana Laboratories Pursuant To The Binding Letter Of Intent; The Next Phase Is The Execution Of A Stock Purchase Agreement To Be Concluded No Later Than March 31, 2023

宇宙健康根據具約束力的意向書與卡納實驗室簽訂重大權威協議;下一階段是執行不遲於 2023 年 3 月 31 日簽訂的股票購買協議
Benzinga ·  2023/03/07 09:18
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has entered into a material definitive agreement with Pharmaceutical Laboratories CANA S.A., ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.
Cosmos Health Inc. (「Cosmos Health」或「本公司」) (NASDAQ: COSM) 是一家全球醫療保健集團,擁有製藥、品牌仿製品、非處方藥物和醫療器材的經銷商,已與製藥實驗室 CANA S.A. (「卡納」) 達成重大權威協議,該公司是一家生產、銷售、銷售原創產品、銷售原創產品的製藥公司 CANA S.A. 並由全球領先的製藥和醫療保健公司開發。
This material definitive agreement is pursuant to the Binding Letter of Intent dated July 19, 2022, and amended on January 10, 2023, which was entered into by Cosmos Health, applicable Cana entities, and...
本重大權威協議是根據日期為 2022 年 7 月 19 日...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論